INTIInhibitor Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Inhibitor Therapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INTIThis | — | — | — | — | — | 1.2%#3 | — | — | — | — | — | — |
| IMRN | $281M#2 | — | — | — | — | — | — | — | — | — | -56.1%#3 | — |
| IMRX | — | — | — | — | -100.0%#4 | 8.2%#2 | — | -33.2%#2 | — | — | -43.8%#2 | — |
| INBP | — | — | — | — | -19.3%#3 | -451.7%#5 | -6.2%#3 | -16.1%#1 | -20.5%#2 | 4#2 | — | — |
| INCR | $275M#3 | — | — | — | — | — | — | — | — | — | — | — |
| INDV | $4.3B#1 | 10.2x#1 | — | 3.5x#1 | 4.3%#1 | 2900.0%#1 | 21.1%#1 | — | 187.2%#1 | 5#1 | 23.5%#1 | — |
| ISCO | — | — | — | — | 0.2%#2 | -100.0%#4 | -2.9%#2 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice